Group 1: Fixed Income/Banking - The overall scale of corporate annuities in China continued to expand in Q4 2025, with a decrease in investment returns compared to the previous quarter [7][8] - The number of enterprises establishing annuity plans increased by 2,730 to 178,000, and the number of insured employees rose by 109,400 to 3,343,000, indicating steady growth in scale metrics [8][9] - The average management scale of insurance funds is higher than that of public funds, with several institutions showing significant growth in both scale and percentage increase [7][11] Group 2: Robotics - Yushu Technology's IPO has been accepted, aiming to become the first humanoid robot company listed on A-shares, with over 5,500 humanoid robots shipped in 2025, ranking first globally [14][15] - The domestic humanoid robot industry is accelerating its capitalized process, with multiple companies completing significant financing rounds in 2026 [15][16] - The government is increasingly prioritizing the embodied intelligence industry, with new national standards being established to support the sector [16][17] Group 3: Construction/Building Materials - Infrastructure fixed asset investment reached 1.88 trillion yuan in January-February 2026, a year-on-year increase of 11.40%, with significant growth in energy and public facilities sectors [23][24] - The issuance of special bonds is accelerating, with a cumulative issuance of 1.048 trillion yuan as of March 22, 2026, reflecting a 50.82% year-on-year increase [24] - The construction investment logic is shifting towards structural investments that serve national strategies and security needs, particularly in energy and water resources [26][27] Group 4: Food and Beverage - China Resources Beer reported a total revenue of 37.985 billion yuan in 2025, a slight decrease of 1.68%, with a net profit of 3.371 billion yuan, down 28.87% due to goodwill impairment in its liquor business [28][30] - The beer segment showed resilience with a revenue of 36.49 billion yuan, maintaining stable performance despite a slight decline in sales volume [29][30] - Wanchen Group achieved a revenue of 51.459 billion yuan in 2025, a year-on-year increase of 59.17%, with a net profit of 1.345 billion yuan, reflecting a significant growth in its snack retail business [32][33] Group 5: Pharmaceuticals - Junshi Biosciences, established in December 2012, focuses on innovative therapies and reported a sales revenue of 2.068 billion yuan for its core product in 2025, a growth of 37.72% [36][37] - The company has multiple potential products in its pipeline that are expected to contribute to revenue growth, including a PD-1/VEGF dual antibody and a CLDN18.2 ADC [37][38] - The company is projected to have total revenues of 3.398 billion yuan in 2026, with a strong emphasis on innovation and clinical development [38]

Investment Rating - The report suggests a positive outlook for the company, indicating that it is significantly undervalued with a market capitalization of only 2.7 billion HKD, and recommends active monitoring of the stock [9]. Core Insights - The company has achieved a remarkable revenue growth of 1344.77% year-on-year, reaching a total revenue of 0.29 billion RMB for the fiscal year 2025, while reducing its net loss by 43.27% to 1.05 billion RMB [1][2]. - Cost control measures have been effective, with administrative expenses reduced by 16.4 million RMB and R&D costs optimized, particularly focusing on the SM17 clinical trials [2]. - The clinical development of SM17 is progressing rapidly, with positive results from the 1b phase study for atopic dermatitis, showing a 91.7% itch relief rate and 75% achieving skin lesion recovery [3]. - The company is building a differentiated pipeline in autoimmune diseases, with a focus on first-in-class (FIC) and best-in-class (BIC) products, which are expected to lead to significant business development opportunities in 2026-2027 [4][9]. Financial Performance - The total available funds increased from 141.4 million RMB in 2024 to 351.5 million RMB, supporting the advancement of the pipeline [2]. - The company has successfully narrowed its losses from 185 million RMB in 2024 to 105 million RMB in 2025 [2]. R&D Pipeline - The company is advancing the SM17 clinical trials for atopic dermatitis and inflammatory bowel disease (IBD), with plans to submit an IND application for idiopathic pulmonary fibrosis (IPF) [3]. - The next-generation anti-CGC antibody is undergoing CMC optimization and toxicology studies, with an IND application for alopecia areata expected by Q4 2026 [7]. - A bispecific antibody targeting osteoporosis is also in development, with plans to submit an IND application by mid-2027, addressing a market with over 200 million patients globally [8].

Investment Rating - The report assigns a "Buy" rating to Fuhong Hanlin (02696) [1] Core Insights - Goldman Sachs has raised the sales forecasts for Fuhong Hanlin by 8.6% for this year and 8.3% for next year, while maintaining the sales forecast for 2028 [1] - The net profit forecasts have been increased by 38 million RMB, 224 million RMB, and 143 million RMB for the respective years [1] - The target price has been adjusted from 102.72 HKD to 104.79 HKD [1] Revenue Performance - Fuhong Hanlin's total revenue for the second half of last year increased by 29% year-on-year to 3.8 billion RMB, with domestic sales exceeding expectations, rising by 31% to 3.2 billion RMB [1] - Overseas revenue for the year reached 258 million RMB, with HLX02 contributing approximately 180 million RMB, primarily from sales in the United States [1] - The strong revenue growth and continuous improvement in gross margin led to better-than-expected profitability in the second half of the year [1]

Investment Rating - The report maintains a "Recommended" rating for the company Fuhong Hanlin (stock code: 2696.HK) [1] Core Insights - Fuhong Hanlin reported a revenue of 6.667 billion yuan for 2025, representing a year-on-year growth of 16.5%, and a net profit of 827 million yuan, with a slight increase of 0.8% [4] - The company has achieved continuous revenue and profit growth for three consecutive years since it first became profitable in 2023 [4] - The global product revenue reached 5.775 billion yuan, with a year-on-year increase of 17.0%, driven by significant sales of core products [4] - The company’s R&D investment for the year was 2.492 billion yuan, reflecting a 35.4% increase year-on-year [4] - The report highlights the successful internationalization of core products, particularly HLX43 and trastuzumab, which have seen substantial overseas sales growth [4] Financial Performance Summary - The company’s projected financial performance for 2026-2028 includes: - Revenue: 8.059 billion yuan in 2026, 7.786 billion yuan in 2027, and 9.486 billion yuan in 2028 - Net profit: 1.018 billion yuan in 2026, 982 million yuan in 2027, and 1.255 billion yuan in 2028 - The projected PE ratios are 34, 36, and 28 for the years 2026, 2027, and 2028 respectively [5] - The gross margin is expected to remain strong, with estimates of 76.43% in 2026 and 74.98% in 2027 and 2028 [5] Product and Market Development - The report emphasizes the global sales performance of key products: - Sales of HLX43 reached 1.493 billion yuan, with a year-on-year growth of 13.7% - Trastuzumab sales amounted to 2.9645 billion yuan, showing a 5.5% increase, and it is now included in multiple national insurance systems [4] - The sales of neratinib surged by 564.2% to 301.2 million yuan, solidifying its position in the HER2-positive early breast cancer treatment market [4] - The company is actively exploring the potential of its innovative pipeline, including ADC and monoclonal antibodies, with promising data presented at international academic conferences [4]

Core Viewpoint - Rongchang Biologics (09995) has seen its stock price increase by over 4%, currently trading at 90.6 HKD, following the announcement of a new indication approval for its self-developed drug, Vidisizumab (brand name: Aidiqi), for the treatment of specific breast cancer populations [1] Group 1: Product Development - The National Medical Products Administration has approved a new indication for Vidisizumab, marking the fourth approved indication for this drug in China [1] - The expansion of indications for Vidisizumab will enhance the company's product matrix and strengthen its core competitiveness [1] Group 2: Market Impact - The drug was successfully included in the Category B directory through the national medical insurance negotiation in 2024, significantly reducing the patient out-of-pocket expenses [1] - This reduction in costs is expected to drive a substantial increase in terminal prescription volumes, laying a solid foundation for the market promotion of the new indication [1]

Summary of the Conference Call for Boya Bio-Pharmaceuticals Company Overview - **Company**: Boya Bio-Pharmaceuticals - **Industry**: Blood products and biopharmaceuticals Key Points Industry and Regulatory Changes - Starting January 2026, the value-added tax on blood products will increase from 3% to 13%, leading to a significant decline in the company's actual pre-tax prices and creating substantial uncertainty for 2026 performance. The company is currently seeking policy exemptions from the State Administration of Taxation [2][8] - The blood products industry is facing increased pressure from price controls and expanded procurement policies, which are expected to impact pricing and inventory levels [4][8] Financial Performance and Projections - In 2025, the company achieved a plasma collection volume of 662.31 tons, a 5% increase year-over-year, with Green Cross contributing 119.91 tons, reflecting a 10.46% growth [2][5] - The consolidated gross margin for 2025 is projected at 49.9%, a decrease of 14.8 percentage points, primarily due to the lower margin of Green Cross and overall industry price pressures [2][5] - The company anticipates that the new production process for Green Cross's immunoglobulin will enhance yield from 1,200-1,300 units/liter to levels comparable to Boya's standards [2][5] Research and Development - The company has accelerated its R&D pipeline, with approvals for 10% concentration immunoglobulin and human tetanus immunoglobulin, and clinical approval for PCC [2][10] - The company aims to expand its international sales, particularly in "Belt and Road" markets, with products currently in the registration phase in various countries [2][10] Strategic Focus and Business Segmentation - Boya is actively divesting non-blood product businesses, having completed the disposal of Boya New and is targeting the divestiture of Nanjing New Hundred by 2026 to focus entirely on blood products [2][14] - The company is implementing integrated management across its 21 plasma stations to enhance efficiency and reduce costs, particularly in key provinces like Jiangxi and Anhui [7][9] Market Competition and Challenges - The introduction of recombinant human albumin is not expected to pose a significant threat in the short term due to its higher costs and limited indications compared to human-derived products [3][13] - The company is exploring ways to manage the competition from imported albumin by discussing potential regulatory adjustments with national authorities [3][13] Future Outlook - The company is optimistic about its growth trajectory, aiming to exceed the industry average growth rate of approximately 5.5% in 2026 [2][5][9] - Despite the challenges posed by regulatory changes and market pressures, the company plans to enhance operational efficiency and maintain a focus on high-quality development through innovation and strategic marketing [17] Conclusion - Boya Bio-Pharmaceuticals is navigating a complex regulatory environment while focusing on growth in its core blood products business. The company is committed to improving operational efficiencies and expanding its market presence, particularly in international markets, while managing the challenges posed by increased taxation and competition.

Core Viewpoint - The article discusses the innovative use of AI in developing a personalized mRNA vaccine for dogs with cancer, highlighting the potential for AI to revolutionize medicine and the future of cancer treatment [3][8][10]. Group 1: The Story of Paul and Rossi - Paul, a 42-year-old Australian entrepreneur and AI engineer, faced a personal crisis when his dog Rossi was diagnosed with cancer [4]. - After traditional treatments failed, Paul turned to AI for help, specifically ChatGPT, which suggested genetic sequencing as a potential solution [5]. - The genetic sequencing of Rossi's tumor revealed significant data, leading to the development of a personalized mRNA vaccine [6][7]. Group 2: The Development of the mRNA Vaccine - The mRNA vaccine was designed to target specific mutations found in Rossi's cancer, marking a significant milestone as the first personalized cancer vaccine for dogs [6][7]. - Despite initial success, the vaccine did not completely cure Rossi, prompting further research and the development of a second vaccine [7]. - The rapid progress in this case has drawn attention from the scientific community, indicating a shift towards citizen science and the democratization of scientific research [9]. Group 3: Implications for Human Medicine - The success of the canine vaccine raises questions about the applicability of similar methods for human cancer treatment, although significant research is still needed [9][10]. - The article emphasizes the transformative potential of AI in drug development, contrasting traditional methods with AI-driven approaches that can significantly reduce time and costs [10]. - The narrative suggests that advancements in AI and mRNA technology could lead to a new era in medicine, where diseases like cancer may be treated more effectively [10][11].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 KN026輔助治療HER2+乳腺癌III期臨床研究完成首例患者給藥 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，旨在知會本集團股東（「股東」）及潛在投資者有關本集團的最新業務發展。 康寧傑瑞生物製藥 本公司董事（「董事」）會（「董事會」）欣然宣佈，與石藥集團有限公司（股份代號： 1093）附屬公司上海津曼特生物科技有限公司合作開發的KN026聯合多西他賽 （白蛋白結合型）(HB1801)和化療輔助治療人表皮生長因子受體2（「HER2」）陽性 （「HER2+」）乳腺癌（「BC」）的一項III期臨床研究（研究編號：KN026-007）已成功 完成首例患者給藥。 BC是中國女性發病率最高的惡性腫瘤，其中HER2+亞型約佔20%至30%。儘管 曲妥珠單抗（聯合或不聯合帕 ...

Financial Data and Key Metrics Changes - The company announced Q4 and full-year financial results, achieving a gross proceeds of $4.1 million from the third tranche of financing triggered by reaching the 50% enrollment milestone in the Nephro CRRT study [5][6]. - As of December 31, the company had cash and investments totaling $20.4 million, which, along with remaining tranches, is expected to provide a runway through a potential FDA approval of Niyad next year [6]. Business Line Data and Key Metrics Changes - The Nephro CRRT study is progressing well, with expectations to complete enrollment later this year and file the PMA within about three months after study completion [6]. Market Data and Key Metrics Changes - The incidence rates of acute kidney injury (AKI) severe enough to require dialysis, particularly continuous renal replacement therapy (CRRT), are increasing, driven by factors such as septic shock and the growing complexity of ICU patients [29][30][40]. Company Strategy and Development Direction - The company aims to address the unmet need for anticoagulation in CRRT circuits, with a focus on nafamostat as a potential solution [3][5]. - The management highlighted the importance of continuous renal replacement therapy in the ICU setting, emphasizing the need for effective anticoagulation strategies to prevent filter clotting [7][44]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the CRRT market, noting that the patient population requiring such therapies is expected to continue increasing due to the aging population and rising chronic kidney disease rates [29][33]. - The management acknowledged the challenges associated with current anticoagulation methods, particularly heparin, and the need for improved alternatives like citrate, despite its complexities [56][101]. Other Important Information - The company is actively involved in discussions about the complexities and challenges of using citrate as an anticoagulant, which has implications for nursing staff and patient safety [141][160]. - The management noted logistical challenges related to the storage and administration of citrate solutions, which can complicate treatment protocols [164][171]. Q&A Session Summary Question: What are the key differences between CRRT and intermittent hemodialysis? - CRRT is used for critically ill patients in the ICU, providing continuous and gentler dialysis, while intermittent hemodialysis is typically for more stable outpatient chronic dialysis patients [21][24]. Question: Are there any trends in the incidence rates of end-stage kidney disease versus acute kidney injury? - The chronic dialysis population is stabilizing, while the incidence of acute kidney injury is increasing, particularly in ICU settings [28][30]. Question: What anticoagulation strategies are being used? - The use of citrate is becoming more common, but it presents challenges in monitoring and administration, while heparin is often avoided due to its inefficacy and bleeding risks [56][101][128].

Financial Data and Key Metrics Changes - In 2025, the company reported total revenue of CNY 2.06 billion, a 6.5% increase compared to the previous year, with commercialized revenue at CNY 540 million [45][46] - Gross margin increased by 16.1% to CNY 1.47 billion, outpacing revenue growth due to a favorable income mix [46][47] - Total loss for the year was CNY 380 million, slightly higher than the previous year, attributed to increased marketing and sales expenses during the first year of commercialization [47][48] Business Line Data and Key Metrics Changes - The company has four launched products with multiple indications, marking the first year of complete commercialization [22][31] - The commercialization team expanded to nearly 600 people, covering over 300 cities and 1,200 medical institutions in China [12][22] - The company has over 30 R&D projects, with 10+ in clinical development stages and one product in NDA [6][8] Market Data and Key Metrics Changes - Three products and four indications were included in the national medical insurance coverage in 2025, enhancing hospital access [27][60] - The company is focusing on building national channels with core distributors accounting for 90% of business [28][29] - The commercialization strategy includes expanding into 400 professional pharmacies, enhancing patient accessibility [29] Company Strategy and Development Direction - The company aims to advance its differentiated pipeline and address unmet clinical needs while optimizing its ADC platform [20][19] - Strategic collaborations are emphasized to enhance the value of the pipeline and expand business footprint globally [10][20] - The focus is on establishing a leading market position in second-line treatments for non-small cell lung cancer and HR-positive breast cancer [62][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in doubling sales in 2026, driven by successful commercialization efforts and product approvals [66] - The company is optimistic about the future, with plans to enhance team capabilities and expand market coverage [66][70] - Management highlighted the importance of data superiority and compliance in driving market access and sales growth [60][63] Other Important Information - The company raised $250 million through H-share placement in 2025 and was included in several global equity indices [13][52] - R&D expenditure was CNY 1.32 billion, a 9.4% increase from the previous year, reflecting stable investment in business expansion [50][51] - The company has a healthy debt-to-asset ratio, with total liabilities at CNY 1.12 billion [53] Q&A Session Questions and Answers Question: What is the expected revenue from licensing and how does it relate to R&D expenses? - Management noted that licensing revenue is accounted for differently and does not correspond directly to R&D expenses, as reimbursement logic varies [67] Question: What are the sales guidance for products other than 264? - Management indicated that 140 has good progress and opportunities due to its unique head-to-head study, while 166 and 167 are also expected to perform well [73][75] Question: When will data for first-line lung cancer be available? - Management anticipates data readouts for first-line lung cancer in Q4 during the ASCO meeting, with ongoing studies expected to yield positive results [57][59]